Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance
about
CAS proteins in normal and pathological cell growth controlTargeting Src family kinases in anti-cancer therapies: turning promise into triumphProtein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell linesNSP-CAS Protein Complexes: Emerging Signaling Modules in CancerLoss of AND-34/BCAR3 expression in mice results in rupture of the adult lensEmbryonal Fyn-associated substrate (EFS) and CASS4: The lesser-known CAS protein family membersBreast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomesGrb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repressionEpidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferationAncestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus.High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells.Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1.Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapyEffects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesisCytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells.Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinaseBCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinibKLF6-SV1 drives breast cancer metastasis and is associated with poor survivalOrphan nuclear receptors in breast cancer pathogenesis and therapeutic response.Bisindole-PBD regulates breast cancer cell proliferation via SIRT-p53 axis.Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancerTLE3 as a candidate biomarker of response to taxane therapy.The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells.CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistanceNuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells.Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells.Immunohistochemical expression of GPR30 in breast carcinoma of Egyptian patients: an association with immunohistochemical subtypes.The transcriptional co-repressor TLE3 suppresses basal signaling on a subset of estrogen receptor α target genes.
P2860
Q24630247-01D494FB-B8EF-4AF2-BB73-8313F9BAF56CQ27025646-C1106BCD-D9BE-4FB3-9D31-83FAC7815DB8Q28259553-54702C34-0147-48B1-87F4-E3CB4D166369Q28281166-B8D35559-B149-473A-9B19-13B5714FA8A3Q28510147-10C2AD4E-582A-4827-818F-5712580E9E72Q28646036-475FABA3-B9EF-4636-A377-27BCE2BF2CD3Q30408424-7C5AC7D9-ECC6-4D73-95C9-B2FE4AAE4DCDQ33528957-5F134C64-1CD7-420B-A417-48A66EF2774DQ33612070-DD5DEF91-7A7D-4726-BDD4-D7EEEF42515AQ33641475-838FBEA1-14FE-4F7A-AAA6-C4DA14E9281CQ33739228-371A5599-9B61-48F5-8C35-F208234F96CDQ33954542-AB442D7F-1B4E-4ABB-8E96-4A8940A1215DQ33958257-36CB91CD-4C98-4FF8-8F5A-6F8BBB3632ADQ34255976-7EEB948E-EAEE-4795-AB16-0569AE7DA3ECQ34273001-FB86EE3E-2695-435C-B158-3BBE71E9944FQ34371359-9815BCE2-31E8-4B0D-913E-FB812DB5CF34Q34387890-A17D9B66-F91B-4A01-A01F-06DA65730E02Q34613612-90E4FA1D-65E0-479D-98DC-8C3C30FB2DFFQ34946215-421B8853-14E5-40C7-A3C5-93959DE542D9Q35118166-FF5ADAEC-F571-43FD-A6AC-B987D9AA8936Q35758871-7445654D-170D-428F-A69D-006F8AB3D69BQ35906736-A187D151-1B98-4310-B05A-37F70BD130A9Q35906949-F1AF597F-3366-483E-AA5D-3E9BED5756C1Q36110285-30857371-C3B7-4765-B4B8-96FB9F9DA82AQ36135818-2F184A53-5586-4F88-875C-6B6A429033ABQ36299102-8A362827-4AEF-4C65-85B8-7D8EB8DE3D1AQ36324431-1861AFF7-6EE1-44CF-A4BD-7991398D4D6AQ36455407-7FF13713-7884-4B2D-8BBF-7D2C765F711AQ36838991-7C2AF867-0227-43D2-9BF6-3F9639A342FCQ37137065-DC5DC926-B80F-4408-99FD-6BBCF58841CFQ37208764-CA558A1B-781E-44FF-B72F-80944B4BCF13Q37298189-727C8B63-DB8D-40D3-92A6-DFF16DEEF27AQ37457732-4CA0AD3E-DDA4-46A7-B917-43D51A44F39EQ37558869-035C2810-E9A5-4BB3-8A55-BE6E266DACADQ37587494-9D8AFBBB-30F1-40CD-831F-DBB770C9F5B1Q37634494-B8CCF372-64DD-429A-84D8-8E2B95481554Q37689922-D76EC46C-81AC-472D-B0A8-7B0E73598BAAQ37696230-757AF7ED-C6CE-4359-8D48-A085FB4D207BQ38392548-78ED6AD6-AFF5-4B89-8281-1B224467D2D1Q38956394-30C3321D-DFCF-42D0-9637-DF99FF3A0810
P2860
Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Relevance of breast cancer ant ...... ssion and tamoxifen resistance
@ast
Relevance of breast cancer ant ...... ssion and tamoxifen resistance
@en
Relevance of breast cancer ant ...... ssion and tamoxifen resistance
@nl
type
label
Relevance of breast cancer ant ...... ssion and tamoxifen resistance
@ast
Relevance of breast cancer ant ...... ssion and tamoxifen resistance
@en
Relevance of breast cancer ant ...... ssion and tamoxifen resistance
@nl
prefLabel
Relevance of breast cancer ant ...... ssion and tamoxifen resistance
@ast
Relevance of breast cancer ant ...... ssion and tamoxifen resistance
@en
Relevance of breast cancer ant ...... ssion and tamoxifen resistance
@nl
P2093
P3181
P356
P1476
Relevance of breast cancer ant ...... ssion and tamoxifen resistance
@en
P2093
Anieta M Sieuwerts
John A Foekens
Jos Veldscholte
Lambert C J Dorssers
Marcel Smid
Marion E Meijer-van Gelder
Maxime P Look
Stefan Sleijfer
Ton van Agthoven
P3181
P356
10.1200/JCO.2008.17.1462
P407
P577
2009-02-01T00:00:00Z